狼疮低疾病活动状态维持≥50%时间与损害累积及死亡率降低相关
基于挪威Tromsø狼疮队列的纵向人群研究,评估了SLE患者随访期间维持LLDAS≥50%时间(LLDAS-50)对损害累积和死亡率的影响。69例(33.5%)患者达到LLDAS-50,校正年龄和性别后,LLDAS-50与严重损害风险降低(HR 0.37,95%CI 0.19-0.73,P<0.01)及死亡率降低(HR 0.31,95%CI 0.16-0.62,P<0.01)显著相关。
要点
- LLDAS-50与SLE患者严重损害风险降低独立相关(HR 0.37)。
- LLDAS-50与SLE患者死亡率降低独立相关(HR 0.31)。
- LLDAS定义含SLEDAI-2K≤4且无主要器官活动、无新发活动、泼尼松≤7.5mg/日等。
核心结论
- 达到LLDAS-50与SLE患者严重损害累积和死亡风险显著降低相关。
研究设计与样本
- 基于挪威Tromsø狼疮队列的纵向人群研究,纳入该地区所有SLE患者。
主要发现
- 69例(33.5%)患者随访期间至少一半时间处于LLDAS(即达到LLDAS-50)。
- 校正年龄和性别后,LLDAS-50与严重损害风险降低相关(HR 0.37,95%CI 0.19-0.73,P<0.01)。
- 校正年龄和性别后,LLDAS-50与死亡率降低相关(HR 0.31,95%CI 0.16-0.62,P<0.01)。
关键数值与推荐
- LLDAS定义:SLEDAI-2K评分≤4且无主要器官系统活动;无新发狼疮疾病活动特征;当前泼尼松(或等效)剂量≤7.5 mg/日;耐受良好的标准维持剂量免疫抑制剂。
- LLDAS-50定义为随访时间至少50%处于LLDAS。
- 严重损害依据SLICC/ACR损害指数评估。
临床怎么用
- 在SLE长期管理中,以维持LLDAS至少一半随访时间为治疗目标可能有助于减少严重损害和死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the impact of achieving Lupus Low Disease Activity State ≥50% of the time (LLDAS-50) on damage accrual and mortality in an inception cohort of patients with systemic lupus erythematosus (SLE). METHODS: We used data from the Tromsø Lupus Cohort, a longitudinal population-based study of all patients with SLE in the 2 northernmost counties in Norway. LLDAS was defined as 1) a Systemic Lupus Erythematosus Disease Activity Index 2000 score of ≤4, with no activity in major organ systems, 2) no new features of lupus disease activity, 3) current therapy with prednisolone (or equivalent) dosage of ≤7.5 mg daily, and 4) well-tolerated standard maintenance dosages of immunosuppressive drugs. RESULTS: A total of 69 patients (33.5%) spent at least half of their follow-up time in LLDAS (thus, achieving LLDAS-50) and had significantly better survival and lower risk of developing severe damage over time, according to the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. After correcting for age and sex, LLDAS-50 was associated with a significant reduction in risk of having severe damage (hazard ratio [HR] 0.37 [95% confidence interval (95% CI) 0.19-0.73], P < 0.01), and also a reduction in mortality (HR 0.31 [95% CI 0.16-0.62], P < 0.01). CONCLUSION: Our study validates the findings of the inception cohort by demonstrating that achievement of LLDAS-50 is associated with a significant reduction in severe damage and, for the first time, demonstrates a reduction in mortality.
引用
- Sharma C, Raymond W, Eilertsen G, et al. Association of Achieving Lupus Low Disease Activity State Fifty Percent of the Time With Both Reduced Damage Accrual and Mortality in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2020. PMID: 30821926. doi:10.1002/acr.23867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。